These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38748596)

  • 1. Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
    Rugo HS; Schmid P; Tolaney SM; Dalenc F; Marmé F; Shi L; Verret W; Shah A; Gharaibeh M; Bardia A; Cortes J
    Oncologist; 2024 Sep; 29(9):768-779. PubMed ID: 38748596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
    Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
    Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Oliveira M; Rugo HS; Howell SJ; Dalenc F; Cortes J; Gomez HL; Hu X; Toi M; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Nowecki Z; Park YH; Sohn JH; Tokunaga E; Yousef S; Zhukova L; Fulford M; Andrews H; Wadsworth I; D'Cruz C; Turner NC;
    Lancet Oncol; 2024 Sep; 25(9):1231-1244. PubMed ID: 39214106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
    Loibl S; Loirat D; Tolaney SM; Punie K; Oliveira M; Rugo HS; Bardia A; Hurvitz SA; Brufsky AM; Kalinsky K; Cortés J; O'Shaughnessy JA; Dieras V; Carey LA; Gianni L; Gharaibeh M; Preger L; Phan S; Chang L; Shi L; Piccart MJ
    Eur J Cancer; 2023 Jan; 178():23-33. PubMed ID: 36379186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
    Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Goswami T; Wegener WA; Bardia A
    Ann Oncol; 2020 Dec; 31(12):1709-1718. PubMed ID: 32946924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
    Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    Bardia A; Rugo HS; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Kalinsky K; Cortés J; Shaughnessy JO; Diéras V; Carey LA; Gianni L; Piccart-Gebhart M; Loibl S; Yoon OK; Pan Y; Hofsess S; Phan SC; Hurvitz SA
    J Clin Oncol; 2024 May; 42(15):1738-1744. PubMed ID: 38422473
    [No Abstract]   [Full Text] [Related]  

  • 10. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    Rugo HS; Bardia A; Marmé F; Cortes J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Pardo PG; Jhaveri KL; Delaney R; Fu O; Lin L; Verret W; Tolaney SM
    J Clin Oncol; 2022 Oct; 40(29):3365-3376. PubMed ID: 36027558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
    Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Spears PA; Tolaney SM
    Future Oncol; 2024 Apr; 20(11):635-651. PubMed ID: 38270051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer.
    Manna M; Brabant M; Greene R; Chamberlain MD; Kumar A; Alimohamed N; Brezden-Masley C
    Curr Oncol; 2024 Sep; 31(9):5694-5708. PubMed ID: 39330050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer.
    Garrigos L; Camacho D; Perez-Garcia JM; Llombart-Cussac A; Cortes J; Antonarelli G
    Expert Rev Anticancer Ther; 2024 Oct; 24(10):949-958. PubMed ID: 39210557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
    Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
    Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.